{
    "root": "52ad9cbf-8084-4415-ab3c-d95dcc2105f1",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "VFEND",
    "value": "20250326",
    "ingredients": [
        {
            "name": "VORICONAZOLE",
            "code": "JFU09I87TR",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_10023"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "POVIDONE, UNSPECIFIED",
            "code": "FZ989GH94E"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "TRIACETIN",
            "code": "XHX3C3X673",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_9661"
        },
        {
            "name": "BETADEX SULFOBUTYL ETHER SODIUM",
            "code": "2PP9364507",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_25698"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        },
        {
            "name": "XANTHAN GUM",
            "code": "TTV12P4NEE",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_189560"
        },
        {
            "name": "TRISODIUM CITRATE DIHYDRATE",
            "code": "B22547B95K"
        },
        {
            "name": "SODIUM BENZOATE",
            "code": "OJ245FE5EU",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_113455"
        },
        {
            "name": "ANHYDROUS CITRIC ACID",
            "code": "XF417D3PSL",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30769"
        },
        {
            "name": "SUCROSE",
            "code": "C151H8M554",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17992"
        }
    ],
    "indications": {
        "text": "vfend azole antifungal indicated treatment adults pediatric patients 2 years age older : \u2022 invasive aspergillosis ( 1.1 ) \u2022 candidemia non-neutropenics deep tissue candida infections ( 1.2 ) \u2022 esophageal candidiasis ( 1.3 ) \u2022 serious fungal infections caused scedosporium apiospermum fusarium species including fusarium solani , patients intolerant , refractory , therapy ( 1.4 )",
        "doid_entities": [
            {
                "text": "invasive aspergillosis (DOID:0050073)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0050073"
            },
            {
                "text": "aspergillosis (DOID:13564)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_13564"
            },
            {
                "text": "esophageal candidiasis (DOID:13146)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_13146"
            },
            {
                "text": "candidiasis (DOID:1508)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1508"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "\u2022 adults ( 2.3 ) infection loading dose maintenance dose intravenous infusion intravenous infusion oral tablets oral suspension invasive aspergillosis 6 mg/kg every 12 hours first 24 hours 4 mg/kg every 12 hours 200 mg every 12 hours 5 ml every 12 hours candidemia nonneutropenics deep tissue candida infections 3\u20134 mg/kg every 12 hours 200 mg every 12 hours 5 ml every 12 hours scedosporiosis fusariosis 4 mg/kg every 12 hours 200 mg every 12 hours 5 ml every 12 hours esophageal candidiasis evaluated evaluated 200 mg every 12 hours 5 ml every 12 hours adult patients weighing less 40 kg : oral maintenance dose 100 mg 150 mg every 12 hours hepatic impairment : half maintenance dose adult patients mild moderate hepatic impairment ( child-pugh class b ) ( 2.5 ) renal impairment : avoid intravenous adult patients moderate severe renal impairment ( creatinine clearance < 50 ml/min ) ( 2.6 ) \u2022 pediatric patients 2 years age older ( 2.4 ) pediatric patients 2 less 12 years age 12 14 years age weighing less 50 kg table . infection loading dose maintenance dose intravenous infusion intravenous infusion oral tablets oral suspension invasive aspergillosis 9 mg/kg every12 hours first 24 hours 8 mg/kg every 12 hours first 24 hours 9 mg/kg every 12 hours ( maximum dose 350 mg every 12 hours ) 0.225 ml/kg every 12 hours [ maximum dose 8.75 ml ( 350 mg ) every 12 hours ] candidemia nonneutropenics deep tissue candida infections scedosporiosis fusariosis esophageal candidiasis evaluated 4 mg/kg every 12 hours 9 mg/kg every 12 hours ( maximum dose 350 mg every 12 hours ) 0.225 ml/kg every 12 hours [ maximum dose 8.75 ml ( 350 mg ) every 12 hours ] pediatric patients aged 12 14 years weighing greater equal 50 kg aged 15 years older regardless body weight adult . ( 2.4 ) adjustment vfend pediatric patients renal hepatic impairment established ( 2.5 , 2.6 ) \u2022 full prescribing information instructions reconstitution vfend lyophilized powder intravenous reconstitution vfend oral suspension important instructions ( 2.1 , 2.6 , 2.7 )",
        "doid_entities": [
            {
                "text": "invasive aspergillosis (DOID:0050073)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0050073"
            },
            {
                "text": "aspergillosis (DOID:13564)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_13564"
            },
            {
                "text": "fusariosis (DOID:0050289)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0050289"
            },
            {
                "text": "esophageal candidiasis (DOID:13146)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_13146"
            },
            {
                "text": "candidiasis (DOID:1508)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1508"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "severe renal impairment",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_447788"
            },
            {
                "disease": "invasive aspergillosis 6",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_1163"
            },
            {
                "disease": "invasive aspergillosis 9",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_1163"
            }
        ]
    },
    "warningsAndPrecautions": null,
    "adverseReactions": "\u2022vfend contraindicated patients known hypersensitivity voriconazole excipients . information regarding cross-sensitivity vfend ( voriconazole ) azole antifungal agents . caution used prescribing vfend patients hypersensitivity azoles . \u2022coadministration pimozide , quinidine ivabradine vfend contraindicated increased plasma concentrations drugs lead qt prolongation rare occurrences torsade de pointes [ ( 7 ) ] . \u2022coadministration vfend sirolimus contraindicated vfend significantly increases sirolimus concentrations [ ( 7 ) pharmacology ( 12.3 ) ] . \u2022coadministration vfend rifampin , carbamazepine , long-acting barbiturates st john 's wort contraindicated drugs likely decrease plasma voriconazole concentrations significantly [ ( 7 ) pharmacology ( 12.3 ) ] . \u2022coadministration standard doses voriconazole efavirenz doses 400 mg every 24 hours higher contraindicated , efavirenz significantly decreases plasma voriconazole concentrations healthy subjects doses . voriconazole also significantly increases efavirenz plasma concentrations [ ( 7 ) pharmacology ( 12.3 ) ] . \u2022coadministration vfend high-dose ritonavir ( 400 mg every 12 hours ) contraindicated ritonavir ( 400 mg every 12 hours ) significantly decreases plasma voriconazole concentrations . coadministration voriconazole low-dose ritonavir ( 100 mg every 12 hours ) avoided , unless assessment benefit/risk patient justifies voriconazole [ ( 7 ) pharmacology ( 12.3 ) ] . \u2022coadministration vfend rifabutin contraindicated since vfend significantly increases rifabutin plasma concentrations rifabutin also significantly decreases voriconazole plasma concentrations [ ( 7 ) pharmacology ( 12.3 ) ] . \u2022coadministration vfend ergot alkaloids ( ergotamine dihydroergotamine ) contraindicated vfend may increase plasma concentration ergot alkaloids , may lead ergotism [ ( 7 ) ] . \u2022coadministration vfend naloxegol contraindicated vfend may increase plasma concentrations naloxegol may precipitate opioid withdrawal symptoms [ ( 7 ) ] . \u2022coadministration vfend tolvaptan contraindicated vfend may increase tolvaptan plasma concentrations increase risk [ ( 7 ) ] . \u2022coadministration vfend venetoclax initiation ramp-up phase contraindicated patients chronic lymphocytic leukemia ( cll ) small lymphocytic lymphoma ( sll ) due potential increased risk tumor lysis syndrome [ ( 7 ) ] . \u2022coadministration vfend lurasidone contraindicated since may result significant increases lurasidone exposure potential serious [ ( 7 ) ] . \u2022 coadministration vfend finerenone contraindicated since may result significant increases finerenone exposure potential serious [ ( 7 ) ] .",
    "indications_original": "VFEND is an azole antifungal indicated for the treatment of adults and pediatric patients 2 years of age and older with: \u2022 Invasive aspergillosis ( 1.1 ) \u2022 Candidemia in non-neutropenics and other deep tissue Candida infections ( 1.2 ) \u2022 Esophageal candidiasis ( 1.3 ) \u2022 Serious fungal infections caused by Scedosporium apiospermum and Fusarium species including Fusarium solani , in patients intolerant of, or refractory to, other therapy ( 1.4 )",
    "contraindications_original": "\u2022 Dosage in Adults ( 2.3 ) Infection Loading dose Maintenance Dose Intravenous infusion Intravenous infusion Oral tablets Oral suspension Invasive Aspergillosis 6 mg/kg every 12 hours for the first 24 hours 4 mg/kg every 12\u00a0hours 200 mg every 12\u00a0hours 5 mL every 12\u00a0hours Candidemia in nonneutropenics and other deep tissue Candida infections 3\u20134 mg/kg every 12\u00a0hours 200 mg every 12\u00a0hours 5 mL every 12\u00a0hours Scedosporiosis and Fusariosis 4 mg/kg every 12\u00a0hours 200 mg every 12\u00a0hours 5 mL every 12\u00a0hours Esophageal Candidiasis Not Evaluated Not Evaluated 200 mg every 12\u00a0hours 5 mL every 12\u00a0hours o Adult patients weighing less than 40 kg: oral maintenance dose 100 mg or 150 mg every 12 hours o Hepatic Impairment : Use half the maintenance dose in adult patients with mild to moderate hepatic impairment (Child-Pugh Class A and B) ( 2.5 ) o Renal Impairment : Avoid intravenous administration in adult patients with moderate to severe renal impairment (creatinine clearance <50 mL/min) ( 2.6 ) \u2022 Dosage in Pediatric Patients 2 years of age and older ( 2.4 ) o For pediatric patients 2 to less than 12 years of age and 12 to 14 years of age weighing less than 50 kg see Table below. Infection Loading Dose Maintenance Dose Intravenous infusion Intravenous infusion Oral\u00a0tablets Oral\u00a0suspension Invasive Aspergillosis 9 mg/kg every12 hours for the first 24 hours 8 mg/kg every 12\u00a0hours after the first 24 hours 9 mg/kg every 12\u00a0hours (maximum dose of 350\u00a0mg every 12\u00a0hours) 0.225 mL/kg every 12 hours [maximum dose of 8.75 mL (350 mg) every 12 hours] Candidemia in nonneutropenics and other deep tissue Candida infections Scedosporiosis and Fusariosis Esophageal Candidiasis Not Evaluated 4 mg/kg every 12\u00a0hours 9 mg/kg every 12\u00a0hours (maximum dose of 350\u00a0mg every 12\u00a0hours) 0.225 mL/kg every 12 hours [maximum dose of 8.75 mL (350 mg) every 12 hours] o For pediatric patients aged 12 to 14 years weighing greater than or equal to 50 kg and those aged 15 years and older regardless of body weight use adult dosage. ( 2.4 ) o Dosage adjustment of VFEND in pediatric patients with renal or hepatic impairment has not been established ( 2.5 , 2.6 ) \u2022 See full prescribing information for instructions on reconstitution of VFEND lyophilized powder for intravenous use and reconstitution of VFEND oral suspension and important administration instructions ( 2.1 , 2.6 , 2.7 )",
    "adverseReactions_original": "\u2022VFEND is contraindicated in patients with known hypersensitivity to voriconazole or its excipients. There is no information regarding cross-sensitivity between VFEND (voriconazole) and other azole antifungal agents. Caution should be used when prescribing VFEND to patients with hypersensitivity to other azoles.\n                     \n                        \u2022Coadministration of pimozide, quinidine or ivabradine with VFEND is contraindicated because increased plasma concentrations of these drugs can lead to QT prolongation and rare occurrences of torsade de pointes [see Drug Interactions (7)].\n                     \n                        \u2022Coadministration of VFEND with sirolimus is contraindicated because VFEND significantly increases sirolimus concentrations [see Drug Interactions (7) and Clinical Pharmacology (12.3)].\n                     \n                        \u2022Coadministration of VFEND with rifampin, carbamazepine, long-acting barbiturates or St John's Wort is contraindicated because these drugs are likely to decrease plasma voriconazole concentrations significantly [see Drug Interactions (7) and Clinical Pharmacology (12.3)].\n                     \n                        \u2022Coadministration of standard doses of voriconazole with efavirenz doses of 400 mg every 24 hours or higher is contraindicated, because efavirenz significantly decreases plasma voriconazole concentrations in healthy subjects at these doses. Voriconazole also significantly increases efavirenz plasma concentrations [see Drug Interactions (7) and Clinical Pharmacology (12.3)].\n                     \n                        \u2022Coadministration of VFEND with high-dose ritonavir (400 mg every 12 hours) is contraindicated because ritonavir (400 mg every 12 hours) significantly decreases plasma voriconazole concentrations. Coadministration of voriconazole and low-dose ritonavir (100 mg every 12 hours) should be avoided, unless an assessment of the benefit/risk to the patient justifies the use of voriconazole [see Drug Interactions (7) and Clinical Pharmacology (12.3)].\n                     \n                        \u2022Coadministration of VFEND with rifabutin is contraindicated since VFEND significantly increases rifabutin plasma concentrations and rifabutin also significantly decreases voriconazole plasma concentrations [see Drug Interactions (7) and Clinical Pharmacology (12.3)].\n                     \n                        \u2022Coadministration of VFEND with ergot alkaloids (ergotamine and dihydroergotamine) is contraindicated because VFEND may increase the plasma concentration of ergot alkaloids, which may lead to ergotism [see Drug Interactions (7)].\n                     \n                        \u2022Coadministration of VFEND with naloxegol is contraindicated because VFEND may increase plasma concentrations of naloxegol which may precipitate opioid withdrawal symptoms [see Drug Interactions (7)].\n                     \n                        \u2022Coadministration of VFEND with tolvaptan is contraindicated because VFEND may increase tolvaptan plasma concentrations and increase risk of adverse reactions [see Drug Interactions (7)]. \n                     \n                        \u2022Coadministration of VFEND with venetoclax at initiation and during the ramp-up phase is contraindicated in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) due to the potential for increased risk of tumor lysis syndrome [see Drug Interactions (7)].\n                     \n                        \u2022Coadministration of VFEND with lurasidone is contraindicated since it may result in significant increases in lurasidone exposure and the potential for serious adverse reactions [see Drug Interactions (7)].\n                     \n                        \u2022\n                        Coadministration of VFEND with finerenone is contraindicated since it may result in significant increases in finerenone exposure and the potential for serious adverse reactions [see \n                        \n                        \n                           Drug Interactions (7)\n                           ].",
    "drug": [
        {
            "name": "VFEND",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_10023"
        }
    ]
}